bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer

Author's Avatar
Mar 28, 2023

%3Cb%3EbioAffinity+Technologies%2C+Inc%3C%2Fb%3E. (NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled %3Ci%3E%26ldquo%3BPorphyrin-modified+beads+for+use+as+compensation+controls+in+flow+cytometry%26rdquo%3B%3C%2Fi%3E in the peer-reviewed Journal of Visualized Experiments (JoVE). The paper describes the protocol for preparing porphyrin-labeled compensation beads to optimize the results of bioAffinity’s CyPath® Lung test to detect early-stage lung cancer.